
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="152543A38AF2E8830543A30021F7D20E.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="openheart">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374655/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Open Heart">
<meta name="citation_title" content="PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs">
<meta name="citation_author" content="Vinh Q T Ho">
<meta name="citation_author_institution" content="Faculty of Medicine, University of Debrecen, Debrecen, Hungary">
<meta name="citation_author" content="Nghi Bao Tran">
<meta name="citation_author_institution" content="Faculty of Medicine, University of Debrecen, Debrecen, Hungary">
<meta name="citation_author" content="Nhan Nguyen">
<meta name="citation_author_institution" content="Faculty of Medicine, University of Debrecen, Debrecen, Hungary">
<meta name="citation_author" content="Giang Son Arrighini">
<meta name="citation_author_institution" content="Faculty of Medicine and Surgery, University of Bologna, Bologna, Italy">
<meta name="citation_author" content="David Downes">
<meta name="citation_author_institution" content="Department of Rural Medicine, University of New England, Armidale, New South Wales, Australia">
<meta name="citation_author" content="Mrunalini Dandamudi">
<meta name="citation_author_institution" content="St Barnabas Health System Bronx, New York, New York, USA">
<meta name="citation_author" content="Victoria Zecchin Ferrara">
<meta name="citation_author_institution" content="Faculty of Medicine and Surgery, University of Padova, Padua, Italy">
<meta name="citation_author" content="Tri Huynh Quang Ho">
<meta name="citation_author_institution" content="Surgical Intensive Care Unit, Ho Chi Minh City Heart Institute, Ho Chi Minh City, Vietnam">
<meta name="citation_author" content="Hemank Walia">
<meta name="citation_author_institution" content="Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA">
<meta name="citation_author" content="Alejandro Barbagelata">
<meta name="citation_author_institution" content="Universidad Catolica Argentina, Buenos AIres, Argentina">
<meta name="citation_author_institution" content="Duke University School of Medicine, Durham, North Carolina, USA">
<meta name="citation_author" content="Thorsten M Leucker">
<meta name="citation_author_institution" content="Johns Hopkins University, Baltimore, Maryland, USA">
<meta name="citation_author" content="Juliana Giorgi">
<meta name="citation_author_institution" content="Hospital Sirio-Libanes, São Paulo, Brazil">
<meta name="citation_author_institution" content="Hospital Albert Einstein, São Paulo, Brazil">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="12">
<meta name="citation_issue" content="2">
<meta name="citation_firstpage" content="e003490">
<meta name="citation_doi" content="10.1136/openhrt-2025-003490">
<meta name="citation_pmid" content="40841123">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374655/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374655/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374655/pdf/openhrt-12-2.pdf">
<meta name="description" content="Familial hypercholesterolaemia (FH) is a hereditary disorder characterised by elevated low-density lipoprotein cholesterol (LDL-C) levels, substantially increasing the risk of atherosclerotic cardiovascular disease. Proprotein convertase ...">
<meta name="og:title" content="PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Familial hypercholesterolaemia (FH) is a hereditary disorder characterised by elevated low-density lipoprotein cholesterol (LDL-C) levels, substantially increasing the risk of atherosclerotic cardiovascular disease. Proprotein convertase ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374655/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374655">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1136/openhrt-2025-003490"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/openhrt-12-2.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374655%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374655/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374655/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374655/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-openheart.png" alt="Open Heart logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Open Heart" title="Link to Open Heart" shape="default" href="http://openheart.bmj.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Open Heart</button></div>. 2025 Aug 21;12(2):e003490. doi: <a href="https://doi.org/10.1136/openhrt-2025-003490" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1136/openhrt-2025-003490</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Open%20Heart%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Open%20Heart%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Open%20Heart%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Open%20Heart%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ho%20VQT%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Vinh Q T Ho</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Vinh Q T Ho</span></h3>
<div class="p">
<sup>1</sup>Faculty of Medicine, University of Debrecen, Debrecen, Hungary</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ho%20VQT%22%5BAuthor%5D" class="usa-link"><span class="name western">Vinh Q T Ho</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tran%20NB%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Nghi Bao Tran</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Nghi Bao Tran</span></h3>
<div class="p">
<sup>1</sup>Faculty of Medicine, University of Debrecen, Debrecen, Hungary</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tran%20NB%22%5BAuthor%5D" class="usa-link"><span class="name western">Nghi Bao Tran</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nguyen%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Nhan Nguyen</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Nhan Nguyen</span></h3>
<div class="p">
<sup>1</sup>Faculty of Medicine, University of Debrecen, Debrecen, Hungary</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nguyen%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nhan Nguyen</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Arrighini%20GS%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Giang Son Arrighini</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Giang Son Arrighini</span></h3>
<div class="p">
<sup>2</sup>Faculty of Medicine and Surgery, University of Bologna, Bologna, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Arrighini%20GS%22%5BAuthor%5D" class="usa-link"><span class="name western">Giang Son Arrighini</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Downes%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">David Downes</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">David Downes</span></h3>
<div class="p">
<sup>3</sup>Department of Rural Medicine, University of New England, Armidale, New South Wales, Australia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Downes%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">David Downes</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dandamudi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Mrunalini Dandamudi</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Mrunalini Dandamudi</span></h3>
<div class="p">
<sup>4</sup>St Barnabas Health System Bronx, New York, New York, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dandamudi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mrunalini Dandamudi</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ferrara%20VZ%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Victoria Zecchin Ferrara</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Victoria Zecchin Ferrara</span></h3>
<div class="p">
<sup>5</sup>Faculty of Medicine and Surgery, University of Padova, Padua, Italy</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ferrara%20VZ%22%5BAuthor%5D" class="usa-link"><span class="name western">Victoria Zecchin Ferrara</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ho%20THQ%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Tri Huynh Quang Ho</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Tri Huynh Quang Ho</span></h3>
<div class="p">
<sup>6</sup>Surgical Intensive Care Unit, Ho Chi Minh City Heart Institute, Ho Chi Minh City, Vietnam</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ho%20THQ%22%5BAuthor%5D" class="usa-link"><span class="name western">Tri Huynh Quang Ho</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Walia%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Hemank Walia</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Hemank Walia</span></h3>
<div class="p">
<sup>7</sup>Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Walia%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hemank Walia</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Barbagelata%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Alejandro Barbagelata</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Alejandro Barbagelata</span></h3>
<div class="p">
<sup>8</sup>Universidad Catolica Argentina, Buenos AIres, Argentina</div>
<div class="p">
<sup>9</sup>Duke University School of Medicine, Durham, North Carolina, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Barbagelata%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alejandro Barbagelata</span></a>
</div>
</div>
<sup>8,</sup><sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leucker%20TM%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Thorsten M Leucker</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Thorsten M Leucker</span></h3>
<div class="p">
<sup>10</sup>Johns Hopkins University, Baltimore, Maryland, USA</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Leucker%20TM%22%5BAuthor%5D" class="usa-link"><span class="name western">Thorsten M Leucker</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Giorgi%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Juliana Giorgi</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Juliana Giorgi</span></h3>
<div class="p">
<sup>11</sup>Hospital Sirio-Libanes, São Paulo, Brazil</div>
<div class="p">
<sup>12</sup>Hospital Albert Einstein, São Paulo, Brazil</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Giorgi%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Juliana Giorgi</span></a>
</div>
</div>
<sup>11,</sup><sup>12</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>Faculty of Medicine, University of Debrecen, Debrecen, Hungary</div>
<div id="aff2">
<sup>2</sup>Faculty of Medicine and Surgery, University of Bologna, Bologna, Italy</div>
<div id="aff3">
<sup>3</sup>Department of Rural Medicine, University of New England, Armidale, New South Wales, Australia</div>
<div id="aff4">
<sup>4</sup>St Barnabas Health System Bronx, New York, New York, USA</div>
<div id="aff5">
<sup>5</sup>Faculty of Medicine and Surgery, University of Padova, Padua, Italy</div>
<div id="aff6">
<sup>6</sup>Surgical Intensive Care Unit, Ho Chi Minh City Heart Institute, Ho Chi Minh City, Vietnam</div>
<div id="aff7">
<sup>7</sup>Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA</div>
<div id="aff8">
<sup>8</sup>Universidad Catolica Argentina, Buenos AIres, Argentina</div>
<div id="aff9">
<sup>9</sup>Duke University School of Medicine, Durham, North Carolina, USA</div>
<div id="aff10">
<sup>10</sup>Johns Hopkins University, Baltimore, Maryland, USA</div>
<div id="aff11">
<sup>11</sup>Hospital Sirio-Libanes, São Paulo, Brazil</div>
<div id="aff12">
<sup>12</sup>Hospital Albert Einstein, São Paulo, Brazil</div>
<div class="author-notes p">
<div class="fn" id="fn1_pmc"><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></div>
<div class="fn" id="fn1"><p>Additional supplemental material is published online only. To view, please visit the journal online (<a href="https://doi.org/10.1136/openhrt-2025-003490" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1136/openhrt-2025-003490</a>).</p></div>
<div class="fn" id="fn4"><p>None declared.</p></div>
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline">Dr Vinh Q T Ho; <span>vinhhoquangtri@gmail.com</span></p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jun 14; Accepted 2025 Jul 30; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</div>
<p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374655  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40841123/" class="usa-link">40841123</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p>Familial hypercholesterolaemia (FH) is a hereditary disorder characterised by elevated low-density lipoprotein cholesterol (LDL-C) levels, substantially increasing the risk of atherosclerotic cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) targeting therapies, including monoclonal antibodies and small interfering RNA (siRNA) agents, have emerged as effective lipid lowering therapies.</p></section><section id="sec2"><h3 class="pmc_sec_title">Objective</h3>
<p>To assess the efficacy and safety of PCSK9-targeting therapy on lipid biomarkers and adverse events in patients with FH, compared with placebo on the background of standard lipid-lowering therapy.</p></section><section id="sec3"><h3 class="pmc_sec_title">Methods</h3>
<p>A systematic review and meta-analysis were conducted, incorporating data from 23 randomised controlled trials involving adult and paediatric FH patients treated with PCSK9 inhibitors (PCSK9i) or siRNA, including alirocumab, bococizumab, evolocumab, tafolecimab and inclisiran. Eligible studies reported changes in LDL-C, apolipoprotein B (ApoB), lipoprotein a (Lp(a)), triglycerides (TGL) and adverse effects. Pooled mean differences (MDs) and ORs with 95% CIs were calculated using random-effects models, and heterogeneity was assessed with I² statistic. This meta-analysis was registered on PROSPERO (CRD42025631510).</p></section><section id="sec4"><h3 class="pmc_sec_title">Results</h3>
<p>A total of 4282 patients were included. PCSK9-targeting therapies significantly reduced LDL-C levels compared with control therapies (MD=−46.64%; 95% CI −50.77% to –42.52%; p&lt;0.00001) and TGL (MD=−15.18%; 95% CI –19.34% to –11.03%; p&lt;0.00001). Significant reductions were also observed for ApoB (MD=−34.94%; 95% CI –40.89% to –28.99%; p&lt;0.00001) and Lp(a) (MD=−22.7%; 95% CI −25.95% to –19.44%; p&lt;0.00001). LDL-C, TGL and ApoB reduction were more significant in heterozygous FH patients than in homozygous patients. The safety profile of these therapies was favourable, with adverse event rates comparable to those of the controls.</p></section><section id="sec5"><h3 class="pmc_sec_title">Conclusions</h3>
<p>PCSK9i and Inclisiran demonstrate significant and sustained reductions in LDL-C, ApoB, Lp(a) and TGL in FH patients, especially in heterozygous FH patients. These agents are generally well-tolerated and represent effective treatment options for FH patients inadequately controlled by standard lipid-lowering therapies.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Pharmacology, Clinical; Biomarkers; Atherosclerosis</p></section></section><hr class="headless">
<section class="bt xbox font-sm" id="BX1"><section id="sec6"><h2 class="pmc_sec_title">WHAT IS ALREADY KNOWN ON THIS TOPIC</h2>
<ul class="list" style="list-style-type:disc"><li><p>PCSK9-targeting therapies have demonstrated strong low-density lipoprotein cholesterol (LDL-C)-lowering effects in adults with familial hypercholesterolaemia (FH), but prior meta-analyses focused mainly on LDL-C and did not include paediatric or homozygous FH populations.</p></li></ul></section><section id="sec7"><h2 class="pmc_sec_title">WHAT THIS STUDY ADDS </h2>
<ul class="list" style="list-style-type:disc"><li><p>This meta-analysis offers the most comprehensive assessment to date, covering 23 randomised controlled trials and evaluating multiple lipid biomarkers (LDL-C, apolipoprotein B, lipoprotein a, triglycerides) and safety outcomes in both adult and paediatric FH populations, including novel therapies like inclisiran, tafelocimab and bococizumab.</p></li></ul></section><section id="sec8"><h2 class="pmc_sec_title">HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY </h2>
<ul class="list" style="list-style-type:disc"><li><p>Findings support broader use of PCSK9-targeting therapies across age groups and FH subtypes and suggest Asian patients may experience enhanced LDL-C reduction with inclisiran, highlighting the potential for personalised lipid-lowering strategies.</p></li></ul></section></section><section id="s1"><h2 class="pmc_sec_title">Introduction</h2>
<p> Familial hypercholesterolaemia (FH) is a prevalent genetic disorder characterised by elevated low-density lipoprotein cholesterol (LDL-C), leading to a significantly increased risk of premature and atherosclerotic cardiovascular disease (ASCVD). The prevalence of heterozygous FH (HeFH) is approximately 1 in 250 individuals, while homozygous FH (HoFH) occurs in about 1 in 300 000 individuals.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1</sup></a> Mutations in genes such as the LDL-C receptor (LDL-R), apolipoprotein B (ApoB) and proprotein convertase subtilisin/kexin type 9 (PCSK9) impair the clearance of LDL-C from the bloodstream, resulting in persistently elevated cholesterol levels.<a href="#R2" class="usa-link" aria-describedby="R2"><sup>2</sup></a></p>
<p>Early diagnosis and treatment are essential to reduce cardiovascular (CV) risk in FH patients.<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3 4</sup></a> Lifestyle modifications have limited impact on LDL-C, making pharmacological therapy the cornerstone of treatment.<a href="#R5" class="usa-link" aria-describedby="R5"><sup>5</sup></a> However, standard therapies such as statins and ezetimibe often fail to achieve LDL-C targets in both adult and paediatric populations,<a href="#R6" class="usa-link" aria-describedby="R6"><sup>6 7</sup></a> prompting the development of novel therapeutic strategies.<a href="#R8" class="usa-link" aria-describedby="R8">8</a>,<a href="#R10" class="usa-link" aria-describedby="R10">10</a></p>
<p>The advent of PCSK9 inhibitors (PCSK9i) as monoclonal antibodies has revolutionised the management of hyperlipidaemia, showing significant efficacy in lowering LDL-C levels and other atherogenic lipids, including triglycerides (TGL), Apo B and lipoprotein a (Lp(a)).<a href="#R11" class="usa-link" aria-describedby="R11">11</a>,<a href="#R17" class="usa-link" aria-describedby="R17">17</a> Inclisiran, a small interfering RNA (siRNA) therapy targeting PCSK9 synthesis, offers a novel mechanism of action with convenient biannual dosing, further enhancing patient adherence and lipid control.<a href="#R18" class="usa-link" aria-describedby="R18"><sup>18</sup></a></p>
<p>This meta-analysis evaluates the efficacy and safety of PCSK9i and siRNA therapies in both adult and paediatric FH patients, focusing on their impact on key lipid biomarkers including LDL-C, TGL, ApoB and Lp(a). The findings aim to support clinical decision-making in FH management.</p></section><section id="s2"><h2 class="pmc_sec_title">Methods</h2>
<p>This systematic review and meta-analysis were performed following the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> and registered at the International Prospective Register of Systematic Reviews (PROSPERO; CRD42025631510).</p>
<section id="s2-1"><h3 class="pmc_sec_title">Search strategy</h3>
<p>We searched PubMed, Embase and Cochrane from inception to January 2025, using the following terms: “PCSK9”; “proprotein convertase subtilisin/kexin”; “PCSK9 inhibitors”; “Inclisiran”; “siRNA”; “small interfering RNA”; “ALN-PCSSC”; “Proprotein convertase subtilisin/kexin type 9 inhibitor”; “Anti-PCSK9 monoclonal antibodies”; “heterozygous familial hypercholesterolemia”; “HeFH”; “heterozygous FH”; “homozygous familial hypercholesterolemia”; “HoFH”; “homozygous FH”; “familial hypercholesterolemia”; “Evolocumab”; “AMG 145”; “Alirocumab”; “REGN727”; “SAR236553”; “Bococizumab”; “RN316”; “PF-04950615”; “LY3015014”. Two authors (VQTH and MD) independently screened titles and abstracts and evaluated the articles for eligibility based on prespecified criteria. Two authors (NBT and NN) independently extracted data related to the outcomes. Discrepancies were resolved through consensus. Data for baseline characteristics (<a href="#T1" class="usa-link">table 1</a>) were extracted by two authors (GSA and VZF).</p>
<section class="tw xbox font-sm" id="T1"><h4 class="obj_head">Table 1. Baseline characteristics of included studies.</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom" rowspan="1" colspan="1">RCT name</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">Patient, n</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">FH subtype</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">Age, years</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">Male, %</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">White, %</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">HTN, %</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">DM, %</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">LDL, mg/dL</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">TG, mg/dL</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">Lp(a), mgdL<a href="#T1_FN3" class="usa-link"><sup>*</sup></a>; nmol/l<a href="#T1_FN4" class="usa-link"><sup>†</sup></a>
</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">ApoB, mg/dL</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">HIS use, %</th>
<th rowspan="2" align="left" valign="bottom" colspan="1">EZ use, %</th>
</tr>
<tr><th align="left" valign="bottom" rowspan="1" colspan="1">Type of intervention</th></tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>ODYSSEY ESCAPE</strong>
<a href="#R24" class="usa-link" aria-describedby="R24">
<sup>24</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">62</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">58.7</td>
<td rowspan="2" align="left" valign="top" colspan="1">58.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">96.8</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">181.11</td>
<td rowspan="2" align="left" valign="top" colspan="1">196.87</td>
<td rowspan="2" align="left" valign="top" colspan="1">32.76<a href="#T1_FN3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">143.4</td>
<td rowspan="2" align="left" valign="top" colspan="1">40.3</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Alirocumab (150 mg Q2W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>ODYSSEY FH I</strong>
<a href="#R16" class="usa-link" aria-describedby="R16">
<sup>16</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">486</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">52.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">56.38</td>
<td rowspan="2" align="left" valign="top" colspan="1">91.3</td>
<td rowspan="2" align="left" valign="top" colspan="1">43.2</td>
<td rowspan="2" align="left" valign="top" colspan="1">11.7</td>
<td rowspan="2" align="left" valign="top" colspan="1">144.6</td>
<td rowspan="2" align="left" valign="top" colspan="1">127.83</td>
<td rowspan="2" align="left" valign="top" colspan="1">49.96<a href="#T1_FN3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">114.3</td>
<td rowspan="2" align="left" valign="top" colspan="1">83.54</td>
<td rowspan="2" align="left" valign="top" colspan="1">57.2</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Alirocumab (75 mg Q2W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>ODYSSEY FH II</strong>
<br>
<a href="#R16" class="usa-link" aria-describedby="R16">
<sup>16</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">249</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">53.2</td>
<td rowspan="2" align="left" valign="top" colspan="1">52.61</td>
<td rowspan="2" align="left" valign="top" colspan="1">98.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">32.5</td>
<td rowspan="2" align="left" valign="top" colspan="1">4.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">134.4</td>
<td rowspan="2" align="left" valign="top" colspan="1">121.23</td>
<td rowspan="2" align="left" valign="top" colspan="1">50.23<a href="#T1_FN3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">107.9</td>
<td rowspan="2" align="left" valign="top" colspan="1">88.35</td>
<td rowspan="2" align="left" valign="top" colspan="1">66.26</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Alirocumab (75 mg Q2W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>ODYSSEY HIGH FH</strong>
<a href="#R25" class="usa-link" aria-describedby="R25">
<sup>25</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">107</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">50.55</td>
<td rowspan="2" align="left" valign="top" colspan="1">53.27</td>
<td rowspan="2" align="left" valign="top" colspan="1">87.85</td>
<td rowspan="2" align="left" valign="top" colspan="1">57.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">14.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">197.85</td>
<td rowspan="2" align="left" valign="top" colspan="1">129.83</td>
<td rowspan="2" align="left" valign="top" colspan="1">27.0<a href="#T1_FN3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">140.92</td>
<td rowspan="2" align="left" valign="top" colspan="1">72.9</td>
<td rowspan="2" align="left" valign="top" colspan="1">24.3</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Alirocumab (150 mg Q2W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>ODYSSEY HoFH</strong>
<a href="#R26" class="usa-link" aria-describedby="R26">
<sup>26</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">69</td>
<td rowspan="2" align="left" valign="top" colspan="1">HoFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">43.38</td>
<td rowspan="2" align="left" valign="top" colspan="1">49.27</td>
<td rowspan="2" align="left" valign="top" colspan="1">78.26</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">282.7</td>
<td rowspan="2" align="left" valign="top" colspan="1">107.17</td>
<td rowspan="2" align="left" valign="top" colspan="1">34.8<a href="#T1_FN3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">186.93</td>
<td rowspan="2" align="left" valign="top" colspan="1">85.5</td>
<td rowspan="2" align="left" valign="top" colspan="1">72.46</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Alirocumab (150 mg Q2W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Santos 2024</strong>
<a href="#R22" class="usa-link" aria-describedby="R22">
<sup>22</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">153</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">12.90</td>
<td rowspan="2" align="left" valign="top" colspan="1">43.14</td>
<td rowspan="2" align="left" valign="top" colspan="1">81.7</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">174.23</td>
<td rowspan="2" align="left" valign="top" colspan="1">79.18</td>
<td rowspan="2" align="left" valign="top" colspan="1">22.65<a href="#T1_FN3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">117.41</td>
<td rowspan="2" align="left" valign="top" colspan="1">15.03</td>
<td rowspan="2" align="left" valign="top" colspan="1">13.72</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Alirocumab (40 mg Q2W; 75 mg Q2W; 150 mg Q4W; 300 mg Q4W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Stein 2012 #1</strong>
<a href="#R23" class="usa-link" aria-describedby="R23">
<sup>23</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">77</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">53.4</td>
<td rowspan="2" align="left" valign="top" colspan="1">61.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">95.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">4.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">155.07</td>
<td rowspan="2" align="left" valign="top" colspan="1">119.57</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">127.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">77.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">71.0</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Alirocumab (150 mg Q4W; 200 mg Q4W; 300 mg Q4W; 150 mg Q2W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Stein 2012 #2</strong>
<a href="#R14" class="usa-link" aria-describedby="R14">
<sup>14</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">21</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">40.43</td>
<td rowspan="2" align="left" valign="top" colspan="1">80.86</td>
<td rowspan="2" align="left" valign="top" colspan="1">85.71</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">133.56</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">112.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">52.38</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Alirocumab (50 mg; 100 mg; 150 mg)<a href="#T1_FN5" class="usa-link"><sup>‡</sup></a>
</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Ridker 2018</strong><a href="#R20" class="usa-link" aria-describedby="R20"><sup>20</sup></a> (SPIRE trials)</td>
<td rowspan="2" align="left" valign="top" colspan="1">1578</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">57.60</td>
<td rowspan="2" align="left" valign="top" colspan="1">58.11</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">59.25</td>
<td rowspan="2" align="left" valign="top" colspan="1">24.9</td>
<td rowspan="2" align="left" valign="top" colspan="1">151.36</td>
<td rowspan="2" align="left" valign="top" colspan="1">139.04</td>
<td rowspan="2" align="left" valign="top" colspan="1">40.41<a href="#T1_FN3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">116.46</td>
<td rowspan="2" align="left" valign="top" colspan="1">80.9</td>
<td rowspan="2" align="left" valign="top" colspan="1">46.94</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Bococizumab (150 mg Q2W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>HAUSER-RCT</strong>
<a href="#R21" class="usa-link" aria-describedby="R21">
<sup>21</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">157</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">13.7</td>
<td rowspan="2" align="left" valign="top" colspan="1">43.7</td>
<td rowspan="2" align="left" valign="top" colspan="1">85.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">3.35</td>
<td rowspan="2" align="left" valign="top" colspan="1">0.66</td>
<td rowspan="2" align="left" valign="top" colspan="1">184.32</td>
<td rowspan="2" align="left" valign="top" colspan="1">86.26</td>
<td rowspan="2" align="left" valign="top" colspan="1">44.9<a href="#T1_FN4" class="usa-link"><sup>†</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">16.6</td>
<td rowspan="2" align="left" valign="top" colspan="1">13.4</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Evolocumab (420 mg Q4W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>RUTHERFORD</strong>
<a href="#R27" class="usa-link" aria-describedby="R27">
<sup>27</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">167</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">49.58</td>
<td rowspan="2" align="left" valign="top" colspan="1">53.29</td>
<td rowspan="2" align="left" valign="top" colspan="1">88.62</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">157.39</td>
<td rowspan="2" align="left" valign="top" colspan="1">124.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">69.83<a href="#T1_FN4" class="usa-link"><sup>†</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">123.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">89.82</td>
<td rowspan="2" align="left" valign="top" colspan="1">64.67</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Evolocumab (350 mg Q4W; 420 mg Q4W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>RUTHERFORD-2</strong>
<a href="#R28" class="usa-link" aria-describedby="R28">
<sup>28</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">329</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">51.15</td>
<td rowspan="2" align="left" valign="top" colspan="1">57.75</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">155.84</td>
<td rowspan="2" align="left" valign="top" colspan="1">116.91</td>
<td rowspan="2" align="left" valign="top" colspan="1">93.61<a href="#T1_FN4" class="usa-link"><sup>†</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">113.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">87.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">62.0</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Evolocumab (140 mg Q2W; 420 mg Q4W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>TESLA</strong>
<a href="#R29" class="usa-link" aria-describedby="R29">
<sup>29</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">49</td>
<td rowspan="2" align="left" valign="top" colspan="1">HoFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">31.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">51.22</td>
<td rowspan="2" align="left" valign="top" colspan="1">90.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">348.03</td>
<td rowspan="2" align="left" valign="top" colspan="1">106.28</td>
<td rowspan="2" align="left" valign="top" colspan="1">92.67<a href="#T1_FN4" class="usa-link"><sup>†</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">210.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">94.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">92.0</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Evolocumab (420 mg Q4W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>CREDIT-2</strong>
<a href="#R30" class="usa-link" aria-describedby="R30">
<sup>30</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">148</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">49.41</td>
<td rowspan="2" align="left" valign="top" colspan="1">52</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">164.35</td>
<td rowspan="2" align="left" valign="top" colspan="1">138.17</td>
<td rowspan="2" align="left" valign="top" colspan="1">28.0<a href="#T1_FN3" class="usa-link"><sup>*</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">121.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">12.16</td>
<td rowspan="2" align="left" valign="top" colspan="1">28.38</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Tafolecimab (150 mg Q2W; 450 mg Q4W)</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>ORION-5</strong>
<a href="#R31" class="usa-link" aria-describedby="R31">
<sup>31</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">56</td>
<td rowspan="2" align="left" valign="top" colspan="1">HoFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">42.7</td>
<td rowspan="2" align="left" valign="top" colspan="1">39.3</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">37.5</td>
<td rowspan="2" align="left" valign="top" colspan="1">5.4</td>
<td rowspan="2" align="left" valign="top" colspan="1">315.3</td>
<td rowspan="2" align="left" valign="top" colspan="1">NA</td>
<td rowspan="2" align="left" valign="top" colspan="1">85.0<a href="#T1_FN4" class="usa-link"><sup>†</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">203.1</td>
<td rowspan="2" align="left" valign="top" colspan="1">100.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">66.1</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Inclisiran sodium (300 mg)<a href="#T1_FN6" class="usa-link"><sup>§</sup></a>
</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>ORION-9</strong>
<a href="#R32" class="usa-link" aria-describedby="R32">
<sup>32</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">482</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">5m6.0</td>
<td rowspan="2" align="left" valign="top" colspan="1">47.1</td>
<td rowspan="2" align="left" valign="top" colspan="1">93.98</td>
<td rowspan="2" align="left" valign="top" colspan="1">42.1</td>
<td rowspan="2" align="left" valign="top" colspan="1">9.96</td>
<td rowspan="2" align="left" valign="top" colspan="1">153.04</td>
<td rowspan="2" align="left" valign="top" colspan="1">123.16</td>
<td rowspan="2" align="left" valign="top" colspan="1">86.33<a href="#T1_FN4" class="usa-link"><sup>†</sup></a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">124.15</td>
<td rowspan="2" align="left" valign="top" colspan="1">73.86</td>
<td rowspan="2" align="left" valign="top" colspan="1">52.9</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Inclisiran sodium (300 mg)<a href="#T1_FN7" class="usa-link"><sup>¶</sup></a>
</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>ORION-15</strong>
<a href="#R33" class="usa-link" aria-describedby="R33">
<sup>33</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">56</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Inclisiran sodium (100 mg, 200 mg, 300 mg)<a href="#T1_FN8" class="usa-link"><sup>**</sup></a>
</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>ORION-18</strong>
<a href="#R34" class="usa-link" aria-describedby="R34">
<sup>34</sup>
</a>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">36</td>
<td rowspan="2" align="left" valign="top" colspan="1">HeFH</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
<td rowspan="2" align="left" valign="top" colspan="1">
<sup>
<a href="#T1_FN9" class="usa-link">††</a>
</sup>
</td>
</tr>
<tr><td align="left" valign="top" rowspan="1" colspan="1">Inclisiran sodium (300 mg)<sup>§§</sup>
</td></tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="T1_FN1"><p>Values are mean or %.</p></div>
<div class="fn" id="T1_FN3">
<sup>*</sup><p class="display-inline">Measured in mg/dL</p>
</div>
<div class="fn" id="T1_FN4">
<sup>†</sup><p class="display-inline">Measured in nmol/L.</p>
</div>
<div class="fn" id="T1_FN5">
<sup>‡</sup><p class="display-inline">Administered on days 1, 29 and 43.</p>
</div>
<div class="fn" id="T1_FN6">
<sup>§</sup><p class="display-inline">Administered on days 1 and 90.</p>
</div>
<div class="fn" id="T1_FN7">
<sup>¶</sup><p class="display-inline">Administered on days 1, 90, 270 and 450.</p>
</div>
<div class="fn" id="T1_FN8">
<sup>**</sup><p class="display-inline">Administered on days 1, 90, 270.</p>
</div>
<div class="fn" id="T1_FN9">
<sup>††</sup><p class="display-inline">Baseline characteristics of FH subgroup in ORION-15 and ORION-18 are not reported, only for the overall population.</p>
</div>
<div class="fn" id="T1_FN2"><p>ApoB, apolipoprotein B; DM, diabetes mellitus; EZ, Ezetimibe; FH, familial hypercholesterolaemia; HeFH, heterozygous familial hypercholesterolaemia; HIS, high-intensity statin; HoFH, homozygous familial hypercholesterolaemia; HTN, hypertension; LDL-C, low-density lipoprotein-cholesterol; Lp(a), lipoprotein(a); NA, not applicable; Q2W, administered every 2 weeks; Q4W, administered every 4 weeks; RCT, randomised controlled trial; TG, triglycerides.</p></div>
</div></section></section><section id="s2-2"><h3 class="pmc_sec_title">Study eligibility</h3>
<p>Studies were eligible if they (1) were RCTs; (2) compared PCSK9i and PCSK9-targeting siRNA to placebo on background of standard lipid-lowering therapies; (3) included HeFH or HoFH; (4) in adults or paediatric populations; (5) had at least one outcome of interest and (6)were published in the English language. We excluded (1) non-RCT (2) studies with overlapping populations; (3) studies with an absence of a control group and (4) studies involving head-to-head comparisons of PCSK9-targeting therapies.</p></section><section id="s2-3"><h3 class="pmc_sec_title">Endpoints</h3>
<p>Outcomes of interest included LDL-C, TGL, ApoB and Lp(a) percentage changes from baseline when comparing PCSK9-targeting therapies (PSCK9i and siRNA therapies) to the control group (placebo on the background of standard lipid-lowering therapies).</p>
<p>The primary safety endpoint was serious adverse events (defined as fatal, life-threatening, required admission to hospital or prolonged stay in hospital, persistent or significant disability or incapacity, congenital anomaly or birth defect, and growth negative impact in paediatric population) related to the drug, and adverse events with treatment discontinuation (injection-site reactions).</p></section><section id="s2-4"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p>We used the Mantel-Haenszel random-effects model for all outcomes. We pooled ORs with 95% CIs for binary endpoints, and weighted mean differences (MDs) for continuous outcomes. All tests were two-tailed, and statistical significance was defined at a p&lt;0.05. Means and SDs were estimated if necessary. Heterogeneity was assessed using Cochrane’s Q test and Higgins and Thompson’s I<sup>2</sup> statistics, with p≤0.10 indicating statistical significance. We determined the consistency of the studies based on I<sup>2</sup> values of 0%, ≤25%, ≤50% and &gt;50%, indicating no heterogeneity, low heterogeneity, moderate heterogeneity and substantial heterogeneity, respectively. Statistical analyses were conducted using Review Manager (RevMan) V.5.4 (Cochrane Center, The Cochrane Collaboration, Denmark).</p></section><section id="s2-5"><h3 class="pmc_sec_title">Subgroup analysis</h3>
<p>Subgroup analyses were conducted to assess differences in treatment efficacy and safety across key clinical and therapeutic factors. Analyses were performed based on: (1) FH subtype (HeFH vs HoFH); (2) drug type and dosing regimen and (3) age group (paediatric vs adult patients). Studies were grouped accordingly, and separate pooled effect estimates were calculated for each subgroup. Statistical differences between subgroups were evaluated using the χ<sup>2</sup> test for subgroup differences, with significance defined as p&lt;0.05.</p></section><section id="s2-6"><h3 class="pmc_sec_title">Quality assessment</h3>
<p>Two independent authors (VQTH and NBT) performed quality assessments of RCTs using the Cochrane Collaboration’s tool for assessing risk of bias in randomised trials (RoB-2). Any disagreements were resolved by consensus between the authors. Publication bias was investigated using a funnel-plot analysis of point estimates and study weights. Leave-one-out sensitivity analyses were performed to ensure the results were not dependent on a single study.</p></section><section id="s2-7"><h3 class="pmc_sec_title">Certainty of the body of evidence</h3>
<p>We assessed the certainty of evidence for each outcome using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, considering five domains: risk of bias, inconsistency, indirectness, imprecision and publication bias. Two reviewers (VQTH and NN) independently rated each outcome, resolving discrepancies by consensus. The Summary of Findings table presents the key results, including effect estimates, CIs, study counts and GRADE ratings (<a href="#SP4" class="usa-link">online supplemental file 2</a>).</p></section><section id="s2-8"><h3 class="pmc_sec_title">Sensitivity analysis</h3>
<p>We performed leave-one-out sensitivity analyses for all lipid biomarkers and adverse event outcomes to explore potential causes of heterogeneity and ensure no single study disproportionately influenced the pooled estimate. Meta-regression analysis was performed to examine the relationship between highly heterogeneous outcomes and baseline lipid biomarker levels, combined treatment and follow-up time. Small-study effects and publication bias were evaluated with Egger’s test and trim-and-fill adjustments. Analyses were conducted in accordance with the PRISMA guidelines.<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a></p></section><section id="s2-9"><h3 class="pmc_sec_title">Patient and public involvement</h3>
<p>Patients and the public were not involved in the design, conduct, reporting or dissemination plans of this study.</p></section></section><section id="s3"><h2 class="pmc_sec_title">Results</h2>
<section id="s3-1"><h3 class="pmc_sec_title">Baseline characteristics</h3>
<p>The search strategy yielded 762 results (<a href="#F1" class="usa-link">figure 1</a>). After removing duplicates and screening titles and abstracts, 26 studies were selected for full-text review. Based on eligibility criteria, 18 studies met all inclusion criteria.<a href="#R14" class="usa-link" aria-describedby="R14">1416 20</a>,<a href="#R34" class="usa-link" aria-describedby="R34">34</a> One of the included studies reported pooled results from six RCTs of the SPIRE trial series (SPIRE-1, SPIRE-2, SPIRE-FH, SPIRE-HR, SPIRE-LDL, SPIRE-LL), comparing bococizumab versus placebo in FH patients, without overlapping populations.<a href="#R20" class="usa-link" aria-describedby="R20"><sup>20</sup></a> Therefore, we included 23 RCTs. Of the 23 included RCTs, 3 studies were conducted exclusively in HoFH patients, including ODYSSEY HoFH, TESLA part B and ORION-5,<a href="#R26" class="usa-link" aria-describedby="R26"><sup>26 29 31</sup></a> while the remaining studies enrolled HeFH patients. The baseline characteristics are summarised in <a href="#T1" class="usa-link">table 1</a>. A total of 4282 FH patients were enrolled, receiving five types of PCSK9 targeting therapies, including alirocumab, bococizumab, evolocumab, tafolecimab and inclisiran. The mean age of the studies ranged from 12.9 to 58.7 years, with two RCTs, Santos 2024 and HAUSER-RCT, conducted in the paediatric population.<a href="#R21" class="usa-link" aria-describedby="R21"><sup>21 22</sup></a> The follow-up duration ranged from 12 weeks to 78 weeks, with the mean baseline LDL-C levels ranging from 133.56±25.31 to 348.03±135.34 mg/DL. In two studies ORION-15 and ORION-18, baseline characteristics specific to the FH subgroup were not reported.<a href="#R33" class="usa-link" aria-describedby="R33"><sup>33 34</sup></a> Therefore, the baseline characteristics for these studies are not included in <a href="#T1" class="usa-link">table 1</a>.</p>
<figure class="fig xbox font-sm" id="F1"><h4 class="obj_head">Figure 1. PRISMA flow diagram of study screening and selection. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374655_openhrt-12-2-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/916a/12374655/0412b095c54b/openhrt-12-2-g001.jpg" loading="lazy" height="699" width="610" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><section id="s3-2"><h3 class="pmc_sec_title">Efficacy outcomes</h3>
<p>In the included 23 RCTs, PCSK9-targeting therapy (PSCK9i and siRNA therapy) showed statistically significant LDL-C reduction (MD=−46.64%; 95% CI −50.77% to –42.52%; p&lt;0.00001; I<sup>2</sup>=82%, <a href="#F2" class="usa-link">figure 2</a>) compared with placebo. Another notable finding was the significant reduction in ApoB levels (MD=−34.94%; 95% CI –40.89% to –28.99%; p&lt;0.00001; I<sup>2</sup>=94%, <a href="#F3" class="usa-link">figure 3</a>), Lp(a) (MD=−22.70%; 95% CI −25.95% to –19.44%; p&lt;0.00001, I<sup>2</sup>=47%, <a href="#F4" class="usa-link">figure 4</a>) and TGL (MD=−15.18%; 95% CI −19.34% to –11.03%; p&lt;0.00001, I<sup>2</sup>=52%, (<a href="#SP3" class="usa-link">online supplemental figure S1</a>).</p>
<figure class="fig xbox font-sm" id="F2"><h4 class="obj_head">Figure 2. LDL-C was statistically significantly reduced with PCSK9 targeting therapies when compared with control group (placebo on the background of standard lipid-lowering therapy) (p&lt;0.00001). FH, familial hypercholesterolaemia; HoFH, homozygous FH; LDL-C, low-density lipoprotein cholesterol; MD, mean difference; RCT, randomised controlled trial.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374655_openhrt-12-2-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/916a/12374655/51fe7c382862/openhrt-12-2-g002.jpg" loading="lazy" height="1100" width="799" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><figure class="fig xbox font-sm" id="F3"><h4 class="obj_head">Figure 3. Apolipoprotein B was statistically significantly reduced with PCSK9 targeting therapies when compared with control group (placebo on the background of standard lipid-lowering therapy) (p&lt;0.00001). FH, familial hypercholesterolaemia; HoFH, homozygous FH; MD, mean difference; RCT, randomised controlled trial.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374655_openhrt-12-2-g003.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/916a/12374655/64d5f016edad/openhrt-12-2-g003.jpg" loading="lazy" height="958" width="799" alt="Figure 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/F3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><figure class="fig xbox font-sm" id="F4"><h4 class="obj_head">Figure 4. Lipoprotein (<strong>a</strong>) was statistically significantly reduced with PCSK9 targeting therapies when compared with control group (placebo on the background of standard lipid-lowering therapy) (p&lt;0.00001). FH, familial hypercholesterolaemia; HoFH, homozygous FH; MD, mean difference; RCT, randomised controlled trial.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374655_openhrt-12-2-g004.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/916a/12374655/01f1d621284d/openhrt-12-2-g004.jpg" loading="lazy" height="890" width="799" alt="Figure 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/F4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>Paediatric populations displayed a substantial reduction of LDL-C levels (MD=−38.15%; 95% CI –43.57% to –32.73%; p&lt;0.00001; I<sup>2</sup>=0%, <a href="#F2" class="usa-link">figure 2</a>) as well as reduction in levels of ApoB (MD=−33.66%; 95% CI% –38.16 to –29.15%; p&lt;0.00001; I<sup>2</sup>=0%, <a href="#F3" class="usa-link">figure 3</a>) and Lp (a) (MD=−17.1%; 95% CI –26.43% to –7.78%; p=0.0003; I<sup>2</sup>=0%, <a href="#F4" class="usa-link">figure 4</a>).</p>
<p>HeFH populations demonstrated a significantly greater response to treatment compared with HoFH populations in the reduction of LDL-C, ApoB and TGL. Among the studies reporting on HeFH patients, PCSK9-targeting therapies led to a significant mean reduction in LDL-C of (MD=–48.50%; 95% CI –52.49% to –44.50%; p&lt;0.00001; I²=80 (<a href="#SP3" class="usa-link">online supplemental figure S2</a>). In contrast, the pooled analysis of 3 studies involving HoFH patients showed a smaller LDL-C reduction (MD=−25.98%; 95% CI −41.68% to –10.27%; p=0.001; I²=62%, <a href="#SP3" class="usa-link">online supplemental figure S2</a>). Similarly, for ApoB reduction, HeFH patients demonstrated a significantly greater treatment response (MD=−36.76%; 95% CI –43.02% to –30.50%; p&lt;0.00001; I²=95%, <a href="#SP3" class="usa-link">online supplemental figure S3</a>) compared with those with HoFH (MD=−21.47%; 95% CI −33.37% to −9.56%; p=0.0004; I²=55%, <a href="#SP3" class="usa-link">online supplemental figure S3</a>). For TGL reduction, the effect was also more pronounced in the HeFH subgroup (MD=−16.50%; 95% CI −20.59% to –12.42%; p&lt;0.00001; I²=47%, <a href="#SP3" class="usa-link">online supplemental figure S4</a>). In contrast, the TGL reduction observed in HoFH patients was smaller and not statistically significant (MD=−5.67%; 95% CI −17.03% to 5.70%; p=0.33; I²=23%, <a href="#SP3" class="usa-link">online supplemental figure S4</a>). The reduction in Lp(a) levels was comparable between HeFH and HoFH populations. In HeFH, the MD was −22.96% (95% CI –26.34% to –19.59%; p&lt;0.00001; I²=48%, <a href="#SP3" class="usa-link">online supplemental figure S5</a>), while in HoFH it was −20.04% (95% CI –36.30% to –3.77; p=0.02; I²=68%, <a href="#SP3" class="usa-link">online supplemental figure S5</a>).</p></section><section id="s3-3"><h3 class="pmc_sec_title">Safety outcomes</h3>
<p>Injection site adverse effects were significant in PCSK9-targeting therapies vs the control group (OR=4.67; 95% CI 3.76 to 5.8; p&lt;0.00001; I<sup>2</sup>=65%; <a href="#F5" class="usa-link">figure 5</a>). Serious adverse effects associated with PCSK9-targeting therapies vs the control group show no statistically significant difference between the two groups (OR=0.99; 95% CI 0.8 to 1.23; p=0.93; I<sup>2</sup>=0%; <a href="#SP3" class="usa-link">online supplemental figure S6</a>). Similarly, adverse effects leading to treatment discontinuation showed no statistically significant difference between the PCSK9-targeting therapies and the control groups (OR=1.31; 95% CI 0.93 to 1.85; p=0.12; I<sup>2</sup>=0%; <a href="#SP3" class="usa-link">online supplemental figure S7</a>).</p>
<figure class="fig xbox font-sm" id="F5"><h4 class="obj_head">Figure 5. Injection site adverse effects caused by subcutaneous injections periodically were statistically increased in the PCSK-9 targeting therapies group when compared with the control group (p&lt;0.00001). FH, familial hypercholesterolaemia; HoFH, homozygous FH; M-H, Mantel-Haenszel; RCT, randomised controlled trial.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374655_openhrt-12-2-g005.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/916a/12374655/cc3dd8ff1da9/openhrt-12-2-g005.jpg" loading="lazy" height="1080" width="740" alt="Figure 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/F5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>In the paediatric populations, the analysis of height impact between PCSK9-targeting therapies and the control group showed no significant difference (MD=0.03 cm; 95% CI −0.41 to 0.47; p=0.89; I<sup>2</sup>=0%; <a href="#SP3" class="usa-link">online supplemental figure S8</a>).</p></section><section id="s3-4"><h3 class="pmc_sec_title">Heterogeneity analysis</h3>
<p>Substantial heterogeneity with I² above 50% was observed for LDL-C (I²=82%), ApoB (I²=94%) and TGL (I²=52%), whereas Lp(a) showed moderate heterogeneity (I²=47%). Subgroup differences were significant in LDL-C (I²=73.5%), ApoB (I²=74.3%), Lp(a) (I²=47.8%) and TGL (I²=74.3%). All findings remained consistent across both fixed and random-effects models.</p>
<p>Injection site adverse events also showed substantial heterogeneity (I²=65%), with SPIRE trials and ODYSSEY FH I identified as major contributors. Their exclusion via leave-one-out analysis reduced I² to 10% and 41%, respectively (<a href="#SP3" class="usa-link">online supplemental figure S9a and b</a>).</p>
<p>In the LDL-C outcome, leave-one-out analysis within the subgroups identified key sources of heterogeneity: excluding Stein 2012 (Alirocumab 150 mg Q2W) and TESLA Part B (Evolocumab 420 mg Q4W) reduced I² to 0% in their respective subgroups (<a href="#SP3" class="usa-link">online supplemental figure S10, S11</a>). In the Inclisiran subgroup, excluding ORION-5 lowered I² from 80% to 63% (<a href="#SP3" class="usa-link">online supplemental figure 12</a>). Moreover, including only ORION-15 and ORION-18 (both 300 mg, Asian cohorts) resulted in I²=0% and a larger LDL-C reduction (MD=−65.60%) compared with the full subgroup (MD=−46.64%; <a href="#SP3" class="usa-link">online supplemental figure S13</a>).</p>
<p>Meta-regression analysis revealed that changes within the placebo cohorts and the year of publication were not significant contributors to the variability in LDL-C, ApoB, Lp(a) or TGL results. Similarly, for injection site adverse effects, year of publication did not significantly drive heterogeneity, with differences in sample size showing a borderline effect (p=0.0747). Influence diagnostic plots of all findings with high heterogeneity confirmed the results of the leave-one-out analysis, noting all the mentioned studies as prominent influential outliers that drove heterogeneity. Finally, trim-and-fill analysis detected no significant publication bias for LDL-C results. For ApoB and Lp(a), minor publication bias was detected. However, the adjusted effect size remained statistically significant. Four potentially missing studies on the left side of the funnel plot were identified for TGL results (<a href="#SP3" class="usa-link">online supplemental figure S14</a>), suggesting that the actual effect may be more substantial than the calculated one. Finally, assessment of the OR for injection site adverse events estimated 10 missing studies on the right side of the funnel plot (<a href="#SP3" class="usa-link">online supplemental figure S15</a>). After adjusting for bias, the OR increased, suggesting that smaller studies with non-significant or negative results may be under-represented.</p></section><section id="s3-5"><h3 class="pmc_sec_title">Risk of bias assessment</h3>
<p>Using the Cochrane Risk of Bias Tool (version 2), we identified 15 of the included studies as having a low risk of bias. Three studies, CREDIT-2, ODYSSEY HoFH and ODYSSEY ESCAPE, were rated as having some concerns regarding the risk of bias. The risk of bias assessment is detailed in <a href="#SP3" class="usa-link">online supplemental table S1</a>.</p></section><section id="s3-6"><h3 class="pmc_sec_title">Certainty of the body of evidence</h3>
<p>Moderate certainty is reported in five outcomes, including the LDL-C, ApoB, injection site adverse effects, serious adverse effects and adverse effects leading to treatment discontinuation. Lp(a) reported high certainty of evidence, while TGL shows low certainty (Summary of Findings table, <a href="#SP4" class="usa-link">online supplemental file 4</a>).</p></section></section><section id="s4"><h2 class="pmc_sec_title">Discussion</h2>
<p>This meta-analysis demonstrates that PSCK9-targeting therapies, such as PCSK9i and siRNA, in adults and paediatric patients with HeFH and HoFH are associated with significantly lower rates of LDL-C, ApoB, TGL and Lp(a) levels, with acceptable safety profiles maintained throughout the follow-up period. The substantial heterogeneity observed likely reflects variations in baseline characteristics, including LDL-C levels, comorbidities and ethnicities. Despite this variability, sensitivity analyses confirmed that LDL-C reductions remained consistently significant across subgroups, underscoring the robustness of PCSK9-targeting therapies. In the Alirocumab 150 mg Q2W subgroup, Stein 2012 emerged as a key source of heterogeneity. This may be attributed to its notably lower baseline LDL-C level (155.07 mg/dL) compared with ODYSSEY ESCAPE (181.11 mg/dL), ODYSSEY HIGH FH (197.85 mg/dL) and ODYSSEY HoFH (282.7 mg/dL), all of which demonstrated more consistent effect sizes (<a href="#T1" class="usa-link">table 1</a>). Similarly, in the Evolocumab 420 mg Q4W subgroup, TESLA Part B likely drove heterogeneity due to its exclusive inclusion of patients with HoFH, whereas RUTHERFORD and RUTHERFORD 2 enrolled HeFH patients. These distinct population profiles likely contributed to the observed between-study variability.</p>
<p>Sensitivity analysis also revealed that using Inclisiran 300 mg exclusively in Asian populations (ORION-15 and ORION-18) resulted in low heterogeneity (I<sup>2</sup>=0%) and significantly greater LDL-C reduction than the entire Inclisiran subgroup (MD=−65.6% compared with MD=−46.64%). This suggests that Asian FH patients may exhibit a particularly strong and consistent response to Inclisiran. Notably, this finding aligns with previous evidence showing that compared with other populations, Asian patients achieve greater LDL-C reductions with Alirocumab, a PCSK9 targeting therapy.<a href="#R35" class="usa-link" aria-describedby="R35"><sup>35</sup></a> Our findings suggest that Inclisiran may offer greater LDL-C reduction in Asian FH patients, underscoring the potential for personalised therapy. Further research is needed to clarify the mechanisms behind this enhanced response.</p>
<p>Subgroup analyses revealed that patients with HeFH consistently experienced greater efficacy from PCSK9-targeting therapies compared with those with HoFH, including the reduction in LDL-C, ApoB and TGL. This may reflect the differences in underlying pathophysiology between the two conditions, as HoFH patients typically have minimal or absent LDL-R activity, potentially limiting the efficacy of PCSK9 inhibition.<a href="#R5" class="usa-link" aria-describedby="R5"><sup>5</sup></a> In contrast, Lp(a) reduction appeared similar between HeFH and HoFH populations, suggesting that the mechanism of PCSK9-targeting therapies on Lp(a) may be independent of LDL-R function. These findings support the use of PCSK9-targeting therapies as especially effective in HeFH patients.</p>
<p>FH is a genetic disorder marked by lifelong elevated LDL-C levels due to mutations in LDLR, LDLRAP1, APOB or PCSK9, which impair LDL-C clearance and accelerate ASCVD development. PCSK9 promotes LDL-R degradation, reducing clearance efficiency. Targeting PCSK9 with monoclonal antibodies or siRNA therapies has proven effective in lowering LDL-C levels. PCSK9 monoclonal antibodies inhibit the protein’s function extracellularly, whereas siRNA therapies reduce hepatic PCSK9 synthesis intracellularly, both resulting in increased LDL-R availability and enhanced LDL-C clearance (<a href="#F6" class="usa-link">figures6 </a><a href="#F7" class="usa-link"> 7</a>).</p>
<figure class="fig xbox font-sm" id="F6"><h3 class="obj_head">Figure 6. Mechanism of action of PCSK9 inhibitors. Left panel: Without PCSK9 inhibitors, PCSK9 binds to LDL receptors (LDLR) on hepatocytes, promoting receptor degradation and reducing LDL clearance, leading to elevated LDL blood levels. Right panel: PCSK9 inhibitors block PCSK9 from binding to LDLR, promoting LDLR recycling and an increase in LDL clearance, resulting in lower LDL-C levels in the bloodstream. Image created with BioRender. LDL-C, low-density lipoprotein cholesterol.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374655_openhrt-12-2-g006.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/916a/12374655/476b11c957e0/openhrt-12-2-g006.jpg" loading="lazy" height="524" width="750" alt="Figure 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/F6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><figure class="fig xbox font-sm" id="F7"><h3 class="obj_head">Figure 7. Mechanism of action of Inclisiran for hypercholesterolaemia. Inclisiran, a small interfering RNA (siRNA) with a GalNAc tail, binds to asialoglycoprotein receptors (ASGPR) on hepatocytes, facilitating its uptake. Inside the cell, Inclisiran forms a RISC complex that binds to PCSK9 mRNA, leading to its degradation and reduced PCSK9 production. Lowered PCSK9 levels result in increased LDL receptor recycling and enhanced clearance of LDL from the bloodstream, causing reduction in LDL-C levels. Image created with BioRender. LDL-C, low-density lipoprotein cholesterol.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374655_openhrt-12-2-g007.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/916a/12374655/4c789c02d7b6/openhrt-12-2-g007.jpg" loading="lazy" height="513" width="766" alt="Figure 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/F7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>Statins and ezetimibe are cornerstone therapies for lowering LDL-C and reducing CV risk.<a href="#R6" class="usa-link" aria-describedby="R6"><sup>6</sup></a> However, their efficacy is often limited in patients with FH, particularly in HoFH, due to the genetic underpinnings of the disorder.<a href="#R5" class="usa-link" aria-describedby="R5"><sup>5</sup></a> Statins function by inhibiting HMG-CoA reductase, leading to upregulation of LDL-R and increased clearance of LDL-C.<a href="#R8" class="usa-link" aria-describedby="R8"><sup>8</sup></a> Ezetimibe inhibits intestinal cholesterol absorption, reducing the amount of cholesterol delivered to the liver and subsequently lowering LDL-C levels.<a href="#R8" class="usa-link" aria-describedby="R8"><sup>8</sup></a> Studies have demonstrated that while statin and ezetimibe can greatly reduce LDL-C levels in the general population, their impact is attenuated in FH patients.<a href="#R4" class="usa-link" aria-describedby="R4"><sup>4</sup></a> The limited efficacy of statins and ezetimibe in FH underscores the need for alternative or adjunctive therapies. PCSK9i, such as alirocumab and evolocumab, has emerged as effective options, offering significant LDL-C reductions even in HoFH populations.<a href="#R26" class="usa-link" aria-describedby="R26"><sup>26 29</sup></a> Additionally, Inclisiran, a siRNA therapy targeting PCSK9 synthesis, provides a novel mechanism of action with the convenience of biannual dosing, further enhancing patient adherence and lipid control.<a href="#R10" class="usa-link" aria-describedby="R10"><sup>10</sup></a></p>
<p>In addition to their potent LDL-C lowering effect, PCSK9-targeting therapies have shown promising results in improving vascular health. In a prospective observational study, treatment with PCSK9 inhibitors led to a significant reduction in pulse wave velocity (PWV), a marker of arterial stiffness, and in inflammatory markers such as the monocyte-to-HDL-cholesterol ratio, suggesting a beneficial impact on vascular function and systemic inflammation in patients with FH.<a href="#R36" class="usa-link" aria-describedby="R36"><sup>36</sup></a> Another study evaluating inclisiran in a real-world setting found a 14.4% reduction in PWV over 6 months, further suggesting that this novel therapy may enhance vascular health together with its lipid-lowering effects.<a href="#R37" class="usa-link" aria-describedby="R37"><sup>37</sup></a></p>
<p>Although PCSK9i have demonstrated strong efficacy in reducing LDL-C levels, real-world adherence and persistence remain relevant challenges. The AT-TARGET-IT study revealed that while overall adherence was high (95.2%), a small proportion of patients showed partial (1.6%) or poor adherence (3.1%).<a href="#R38" class="usa-link" aria-describedby="R38"><sup>38</sup></a> These findings highlight that despite strong efficacy, patient adherence can be affected by injection concerns, side effects and a lack of understanding of LDL-C goals. In clinical practice, improving patient education, addressing injection-related concerns and ensuring consistent follow-up could enhance adherence and persistence with PCSK9-targeting therapies. Inclisiran, with its twice-yearly dosing regimen following initial loading doses, may offer a practical advantage in this regard. By reducing the frequency of administration, Inclisiran has the potential to enhance adherence compared with more frequently dosed monoclonal antibodies. Moreover, inclisiran’s favourable tolerability profile and infrequent dosing regimen also make it an attractive option for patients who are intolerant to statins, which is a common problem in routine clinical practice.<a href="#R39" class="usa-link" aria-describedby="R39"><sup>39</sup></a></p>
<p>Compared with previous literature, this meta-analysis provides a more comprehensive and clinically relevant pooled analysis by incorporating 23 RCTs with 4282 patients in both adult and paediatric populations, including HeFH and HoFH patients. Notably, previous meta-analyses<a href="#R40" class="usa-link" aria-describedby="R40"><sup>40 41</sup></a> did not include paediatric and HoFH populations. Unlike prior studies,<a href="#R40" class="usa-link" aria-describedby="R40"><sup>40 41</sup></a> which focused primarily on monoclonal antibodies or LDL-C outcomes alone, our analysis evaluated a broader range of PCSK9-targeting therapies, including Inclisiran and less studied agents such as tafelocimab and bococizumab and examined multiple lipid biomarkers (LDL-C, TGL, ApoB and Lp(a)). We also included paediatric-specific outcomes such as height impact and assessed tolerability through adverse events leading to discontinuation, which were not addressed in earlier meta-analyses. By comparing these therapies to placebo on the background of standard lipid-lowering treatment, our findings better reflect real-world practice.</p>
<p>PCSK9-targeting therapies, including the recent addition of Inclisiran, have expanded treatment options for FH patients. Their favourable safety profile and ability to lower LDL-C, ApoB and Lp(a) support their role as a key therapy for CV risk reduction in FH patients. Additionally, emerging treatments like ANGPTL3 inhibitors show promise for difficult cases, such as HoFH and severe hypertriglyceridaemia.<a href="#R42" class="usa-link" aria-describedby="R42"><sup>42</sup></a></p>
<section id="s4-1"><h3 class="pmc_sec_title">Study limitations</h3>
<p>Heterogeneity in trial designs and populations warrants cautious interpretation of pooled estimates. Furthermore, long-term CV outcomes associated with Inclisiran remain under investigation, particularly in ORION-5, which includes a more severely affected HoFH population. While ORION-15 and ORION-18 demonstrated promising short-term efficacy in LDL-C reduction, especially among Asian cohorts, both studies lack detailed reporting of baseline characteristics specific to FH patients. This limits the ability to fully contextualise the observed responses and assess the generalisability of findings to broader FH populations. ORION-15 and ORION-18 also lack report of safety outcomes specific to FH patients.</p></section></section><section id="s5"><h2 class="pmc_sec_title">Conclusions</h2>
<p>PCSK9i and Inclisiran are highly effective in lowering LDL-C levels in FH patients, demonstrating sustained efficacy across various subgroups, including the paediatric population. HeFH patients showed a greater response to PCSK9-targeting therapies compared with HoFH patients, particularly in reducing LDL-C, ApoB and TGL levels. Asian FH cohorts demonstrated a notably stronger LDL-C response to Inclisiran compared with the overall FH population. In addition to LDL-C reduction, these therapies significantly lower ApoB and Lp(a) levels, and to some extent, TGL levels, providing CV benefits by targeting multiple lipid biomarkers associated with ASCVD risk. Furthermore, these therapies have a favourable safety profile, with minimal significant adverse events reported, making them a well-tolerated and promising treatment option for patients with persistently high LDL-C levels despite standard lipid-lowering therapies. Long-term follow-up, especially with siRNA therapy, is necessary for a better understanding of this new and revolutionary drug class in the HF population.</p></section><section id="s6"><h2 class="pmc_sec_title">Supplementary material</h2>
<section class="sm xbox font-sm" id="SP1"><div class="caption p"><span>online supplemental file 1</span></div>
<div class="media p" id="d67e1663">
<div class="caption">
<a href="/articles/instance/12374655/bin/openhrt-12-2-s001.tif" data-ga-action="click_feat_suppl" class="usa-link">openhrt-12-2-s001.tif</a><sup> (748.8KB, tif) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/openhrt-2025-003490</div>
</div></section><section class="sm xbox font-sm" id="SP3"><div class="caption p"><span>online supplemental file 3</span></div>
<div class="media p" id="d67e1668">
<div class="caption">
<a href="/articles/instance/12374655/bin/openhrt-12-2-s002.docx" data-ga-action="click_feat_suppl" class="usa-link">openhrt-12-2-s002.docx</a><sup> (4.6MB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/openhrt-2025-003490</div>
</div></section><section class="sm xbox font-sm" id="SP4"><div class="caption p"><span>online supplemental file 4</span></div>
<div class="media p" id="d67e1673">
<div class="caption">
<a href="/articles/instance/12374655/bin/openhrt-12-2-s003.docx" data-ga-action="click_feat_suppl" class="usa-link">openhrt-12-2-s003.docx</a><sup> (41.3KB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/openhrt-2025-003490</div>
</div></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn13"><p><strong>Funding:</strong> The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.</p></div>
<div class="fn p" id="fn14"><p><strong>Provenance and peer review:</strong> Not commissioned; externally peer reviewed.</p></div>
<div class="fn p" id="fn15"><p><strong>Patient consent for publication:</strong> Not applicable.</p></div>
<div class="fn p" id="fn16"><p><strong>Ethics approval:</strong> Not applicable.</p></div>
</div></section><section id="sec31"><h2 class="pmc_sec_title">Data availability statement</h2>
<p>Data are available in a public, open access repository.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="R1">
<span class="label">1.</span><cite>Hu P, Dharmayat KI, Stevens CAT, et al.  Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation. 2020;141:1742–59. doi: 10.1161/CIRCULATIONAHA.119.044795.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.119.044795" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32468833/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Prevalence%20of%20familial%20hypercholesterolemia%20among%20the%20general%20population%20and%20patients%20with%20atherosclerotic%20cardiovascular%20disease:%20a%20systematic%20review%20and%20meta-analysis&amp;author=P%20Hu&amp;author=KI%20Dharmayat&amp;author=CAT%20Stevens&amp;volume=141&amp;publication_year=2020&amp;pages=1742-59&amp;pmid=32468833&amp;doi=10.1161/CIRCULATIONAHA.119.044795&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R2">
<span class="label">2.</span><cite>Goldberg AC, Hopkins PN, Toth PP, et al.  Familial hypercholesterolemia: screening, diagnosis, and management of pediatric and adult patients: clinical guidance from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5:S1–8. doi: 10.1016/j.jacl.2011.04.003.</cite> [<a href="https://doi.org/10.1016/j.jacl.2011.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21600525/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Lipidol&amp;title=Familial%20hypercholesterolemia:%20screening,%20diagnosis,%20and%20management%20of%20pediatric%20and%20adult%20patients:%20clinical%20guidance%20from%20the%20national%20lipid%20association%20expert%20panel%20on%20familial%20hypercholesterolemia&amp;author=AC%20Goldberg&amp;author=PN%20Hopkins&amp;author=PP%20Toth&amp;volume=5&amp;publication_year=2011&amp;pages=S1-8&amp;pmid=21600525&amp;doi=10.1016/j.jacl.2011.04.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R3">
<span class="label">3.</span><cite>Wiegman A, Gidding SS, Watts GF, et al.  Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425–37. doi: 10.1093/eurheartj/ehv157.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehv157" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4576143/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26009596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Familial%20hypercholesterolaemia%20in%20children%20and%20adolescents:%20gaining%20decades%20of%20life%20by%20optimizing%20detection%20and%20treatment&amp;author=A%20Wiegman&amp;author=SS%20Gidding&amp;author=GF%20Watts&amp;volume=36&amp;publication_year=2015&amp;pages=2425-37&amp;pmid=26009596&amp;doi=10.1093/eurheartj/ehv157&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R4">
<span class="label">4.</span><cite>Nordestgaard BG, Chapman MJ, Humphries SE, et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478–90. doi: 10.1093/eurheartj/eht273.</cite> [<a href="https://doi.org/10.1093/eurheartj/eht273" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3844152/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23956253/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Familial%20hypercholesterolaemia%20is%20underdiagnosed%20and%20undertreated%20in%20the%20general%20population:%20guidance%20for%20clinicians%20to%20prevent%20coronary%20heart%20disease:%20consensus%20statement%20of%20the%20European%20Atherosclerosis%20Society&amp;author=BG%20Nordestgaard&amp;author=MJ%20Chapman&amp;author=SE%20Humphries&amp;volume=34&amp;publication_year=2013&amp;pages=3478-90&amp;pmid=23956253&amp;doi=10.1093/eurheartj/eht273&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R5">
<span class="label">5.</span><cite>Cuchel M, Bruckert E, Ginsberg HN, et al.  Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146–57. doi: 10.1093/eurheartj/ehu274.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehu274" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4139706/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25053660/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Homozygous%20familial%20hypercholesterolaemia:%20new%20insights%20and%20guidance%20for%20clinicians%20to%20improve%20detection%20and%20clinical%20management.%20A%20position%20paper%20from%20the%20Consensus%20Panel%20on%20Familial%20Hypercholesterolaemia%20of%20the%20European%20Atherosclerosis%20Society&amp;author=M%20Cuchel&amp;author=E%20Bruckert&amp;author=HN%20Ginsberg&amp;volume=35&amp;publication_year=2014&amp;pages=2146-57&amp;pmid=25053660&amp;doi=10.1093/eurheartj/ehu274&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R6">
<span class="label">6.</span><cite>Mach F, Baigent C, Catapano AL, et al.  ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111–88. doi: 10.1093/eurheartj/ehz455.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehz455" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31504418/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=ESC/EAS%20guidelines%20for%20the%20management%20of%20dyslipidaemias:%20lipid%20modification%20to%20reduce%20cardiovascular%20risk&amp;author=F%20Mach&amp;author=C%20Baigent&amp;author=AL%20Catapano&amp;volume=41&amp;publication_year=2019&amp;pages=111-88&amp;pmid=31504418&amp;doi=10.1093/eurheartj/ehz455&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R7">
<span class="label">7.</span><cite>Grundy SM, Stone NJ, Bailey AL, et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;139:e1082–143. doi: 10.1161/CIR.0000000000000625.</cite> [<a href="https://doi.org/10.1161/CIR.0000000000000625" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7403606/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30586774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=2018%20AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA%20guideline%20on%20the%20management%20of%20blood%20cholesterol:%20a%20report%20of%20the%20American%20college%20of%20cardiology/American%20heart%20association%20task%20force%20on%20clinical%20practice%20guidelines&amp;author=SM%20Grundy&amp;author=NJ%20Stone&amp;author=AL%20Bailey&amp;volume=139&amp;publication_year=2019&amp;pages=e1082-143&amp;pmid=30586774&amp;doi=10.1161/CIR.0000000000000625&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R8">
<span class="label">8.</span><cite>Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262–8. doi: 10.1016/j.atherosclerosis.2012.02.019.</cite> [<a href="https://doi.org/10.1016/j.atherosclerosis.2012.02.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22398274/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Atherosclerosis&amp;title=Homozygous%20familial%20hypercholesterolemia:%20current%20perspectives%20on%20diagnosis%20and%20treatment&amp;author=FJ%20Raal&amp;author=RD%20Santos&amp;volume=223&amp;publication_year=2012&amp;pages=262-8&amp;pmid=22398274&amp;doi=10.1016/j.atherosclerosis.2012.02.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R9">
<span class="label">9.</span><cite>Raal FJ, Rosenson RS, Reeskamp LF, et al.  Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711–20. doi: 10.1056/NEJMoa2004215.</cite> [<a href="https://doi.org/10.1056/NEJMoa2004215" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32813947/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Evinacumab%20for%20homozygous%20familial%20hypercholesterolemia&amp;author=FJ%20Raal&amp;author=RS%20Rosenson&amp;author=LF%20Reeskamp&amp;volume=383&amp;publication_year=2020&amp;pages=711-20&amp;pmid=32813947&amp;doi=10.1056/NEJMoa2004215&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R10">
<span class="label">10.</span><cite>Ray KK, Landmesser U, Leiter LA, et al.  Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430–40. doi: 10.1056/NEJMoa1615758.</cite> [<a href="https://doi.org/10.1056/NEJMoa1615758" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28306389/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Inclisiran%20in%20patients%20at%20high%20cardiovascular%20risk%20with%20elevated%20LDL%20cholesterol&amp;author=KK%20Ray&amp;author=U%20Landmesser&amp;author=LA%20Leiter&amp;volume=376&amp;publication_year=2017&amp;pages=1430-40&amp;pmid=28306389&amp;doi=10.1056/NEJMoa1615758&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R11">
<span class="label">11.</span><cite>Sabatine MS, Giugliano RP, Keech AC, et al.  Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. doi: 10.1056/NEJMoa1615664.</cite> [<a href="https://doi.org/10.1056/NEJMoa1615664" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28304224/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Evolocumab%20and%20clinical%20outcomes%20in%20patients%20with%20cardiovascular%20disease&amp;author=MS%20Sabatine&amp;author=RP%20Giugliano&amp;author=AC%20Keech&amp;volume=376&amp;publication_year=2017&amp;pages=1713-22&amp;pmid=28304224&amp;doi=10.1056/NEJMoa1615664&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R12">
<span class="label">12.</span><cite>Robinson JG, Farnier M, Krempf M, et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–99. doi: 10.1056/NEJMoa1501031.</cite> [<a href="https://doi.org/10.1056/NEJMoa1501031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25773378/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Efficacy%20and%20safety%20of%20alirocumab%20in%20reducing%20lipids%20and%20cardiovascular%20events&amp;author=JG%20Robinson&amp;author=M%20Farnier&amp;author=M%20Krempf&amp;volume=372&amp;publication_year=2015&amp;pages=1489-99&amp;pmid=25773378&amp;doi=10.1056/NEJMoa1501031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R13">
<span class="label">13.</span><cite>Huo Y, Chen B, Lian Q, et al.  Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Lancet Reg Health West Pac. 2023;41 doi: 10.1016/j.lanwpc.2023.100907.</cite> [<a href="https://doi.org/10.1016/j.lanwpc.2023.100907" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10558773/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37808342/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Reg%20Health%20West%20Pac&amp;title=Tafolecimab%20in%20Chinese%20patients%20with%20non-familial%20hypercholesterolemia%20(CREDIT-1):%20a%2048-week%20randomized,%20double-blind,%20placebo-controlled%20phase%203%20trial&amp;author=Y%20Huo&amp;author=B%20Chen&amp;author=Q%20Lian&amp;volume=41&amp;publication_year=2023&amp;pmid=37808342&amp;doi=10.1016/j.lanwpc.2023.100907&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R14">
<span class="label">14.</span><cite>Stein EA, Mellis S, Yancopoulos GD, et al.  Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108–18. doi: 10.1056/NEJMoa1105803.</cite> [<a href="https://doi.org/10.1056/NEJMoa1105803" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22435370/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Effect%20of%20a%20monoclonal%20antibody%20to%20PCSK9%20on%20LDL%20cholesterol&amp;author=EA%20Stein&amp;author=S%20Mellis&amp;author=GD%20Yancopoulos&amp;volume=366&amp;publication_year=2012&amp;pages=1108-18&amp;pmid=22435370&amp;doi=10.1056/NEJMoa1105803&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R15">
<span class="label">15.</span><cite>Sabatine MS, Giugliano RP, Wiviott SD, et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–9. doi: 10.1056/NEJMoa1500858.</cite> [<a href="https://doi.org/10.1056/NEJMoa1500858" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25773607/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Efficacy%20and%20safety%20of%20evolocumab%20in%20reducing%20lipids%20and%20cardiovascular%20events&amp;author=MS%20Sabatine&amp;author=RP%20Giugliano&amp;author=SD%20Wiviott&amp;volume=372&amp;publication_year=2015&amp;pages=1500-9&amp;pmid=25773607&amp;doi=10.1056/NEJMoa1500858&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R16">
<span class="label">16.</span><cite>Kastelein JJ, Ginsberg HN, Langslet G, et al.  ODYSSEY FH I and FH II: efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia. Eur Heart J. 2015;36:2996–3003. doi: 10.1093/eurheartj/ehv370.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehv370" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4644253/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26330422/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=ODYSSEY%20FH%20I%20and%20FH%20II:%20efficacy%20and%20safety%20of%20alirocumab%20in%20patients%20with%20heterozygous%20familial%20hypercholesterolemia&amp;author=JJ%20Kastelein&amp;author=HN%20Ginsberg&amp;author=G%20Langslet&amp;volume=36&amp;publication_year=2015&amp;pages=2996-3003&amp;pmid=26330422&amp;doi=10.1093/eurheartj/ehv370&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R17">
<span class="label">17.</span><cite>Blom DJ, Hala T, Bolognese M, et al.  A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809–19. doi: 10.1056/NEJMoa1316222.</cite> [<a href="https://doi.org/10.1056/NEJMoa1316222" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24678979/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=A%2052-week%20placebo-controlled%20trial%20of%20evolocumab%20in%20hyperlipidemia&amp;author=DJ%20Blom&amp;author=T%20Hala&amp;author=M%20Bolognese&amp;volume=370&amp;publication_year=2014&amp;pages=1809-19&amp;pmid=24678979&amp;doi=10.1056/NEJMoa1316222&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R18">
<span class="label">18.</span><cite>Ray KK, Wright RS, Kallend D, et al.  Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–19. doi: 10.1056/NEJMoa1912387.</cite> [<a href="https://doi.org/10.1056/NEJMoa1912387" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32187462/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Two%20phase%203%20trials%20of%20inclisiran%20in%20patients%20with%20elevated%20LDL%20cholesterol&amp;author=KK%20Ray&amp;author=RS%20Wright&amp;author=D%20Kallend&amp;volume=382&amp;publication_year=2020&amp;pages=1507-19&amp;pmid=32187462&amp;doi=10.1056/NEJMoa1912387&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R19">
<span class="label">19.</span><cite>Page MJ, McKenzie JE, Bossuyt PM, et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372 doi: 10.1136/bmj.n71.</cite> [<a href="https://doi.org/10.1136/bmj.n71" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8005924/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33782057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=The%20PRISMA%202020%20statement:%20an%20updated%20guideline%20for%20reporting%20systematic%20reviews&amp;author=MJ%20Page&amp;author=JE%20McKenzie&amp;author=PM%20Bossuyt&amp;volume=372&amp;publication_year=2021&amp;pmid=33782057&amp;doi=10.1136/bmj.n71&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R20">
<span class="label">20.</span><cite>Ridker PM, Rose LM, Kastelein JJP, et al.  Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: results from the SPIRE randomized trials of bococizumab. J Clin Lipidol. 2018;12:958–65. doi: 10.1016/j.jacl.2018.03.088.</cite> [<a href="https://doi.org/10.1016/j.jacl.2018.03.088" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29685591/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Lipidol&amp;title=Cardiovascular%20event%20reduction%20with%20PCSK9%20inhibition%20among%201578%20patients%20with%20familial%20hypercholesterolemia:%20results%20from%20the%20SPIRE%20randomized%20trials%20of%20bococizumab&amp;author=PM%20Ridker&amp;author=LM%20Rose&amp;author=JJP%20Kastelein&amp;volume=12&amp;publication_year=2018&amp;pages=958-65&amp;pmid=29685591&amp;doi=10.1016/j.jacl.2018.03.088&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R21">
<span class="label">21.</span><cite>Santos RD, Ruzza A, Hovingh GK, et al.  Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med. 2020;383:1317–27. doi: 10.1056/NEJMoa2019910.</cite> [<a href="https://doi.org/10.1056/NEJMoa2019910" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32865373/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Evolocumab%20in%20pediatric%20heterozygous%20familial%20hypercholesterolemia&amp;author=RD%20Santos&amp;author=A%20Ruzza&amp;author=GK%20Hovingh&amp;volume=383&amp;publication_year=2020&amp;pages=1317-27&amp;pmid=32865373&amp;doi=10.1056/NEJMoa2019910&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R22">
<span class="label">22.</span><cite>Santos RD, Wiegman A, Caprio S, et al.  Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial. JAMA Pediatr. 2024;178:283–93. doi: 10.1001/jamapediatrics.2023.6477.</cite> [<a href="https://doi.org/10.1001/jamapediatrics.2023.6477" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10845038/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38315470/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Pediatr&amp;title=Alirocumab%20in%20pediatric%20patients%20with%20heterozygous%20familial%20hypercholesterolemia:%20a%20randomized%20clinical%20trial&amp;author=RD%20Santos&amp;author=A%20Wiegman&amp;author=S%20Caprio&amp;volume=178&amp;publication_year=2024&amp;pages=283-93&amp;pmid=38315470&amp;doi=10.1001/jamapediatrics.2023.6477&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R23">
<span class="label">23.</span><cite>Stein EA, Gipe D, Bergeron J, et al.  Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29–36. doi: 10.1016/S0140-6736(12)60771-5.</cite> [<a href="https://doi.org/10.1016/S0140-6736(12)60771-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22633824/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Effect%20of%20a%20monoclonal%20antibody%20to%20PCSK9,%20REGN727/SAR236553,%20to%20reduce%20low-density%20lipoprotein%20cholesterol%20in%20patients%20with%20heterozygous%20familial%20hypercholesterolaemia%20on%20stable%20statin%20dose%20with%20or%20without%20ezetimibe%20therapy:%20a%20phase%202%20randomised%20controlled%20trial&amp;author=EA%20Stein&amp;author=D%20Gipe&amp;author=J%20Bergeron&amp;volume=380&amp;publication_year=2012&amp;pages=29-36&amp;pmid=22633824&amp;doi=10.1016/S0140-6736(12)60771-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R24">
<span class="label">24.</span><cite>Moriarty PM, Parhofer KG, Babirak SP, et al.  Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37:3588–95. doi: 10.1093/eurheartj/ehw388.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehw388" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5233802/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27572070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Alirocumab%20in%20patients%20with%20heterozygous%20familial%20hypercholesterolaemia%20undergoing%20lipoprotein%20apheresis:%20the%20ODYSSEY%20ESCAPE%20trial&amp;author=PM%20Moriarty&amp;author=KG%20Parhofer&amp;author=SP%20Babirak&amp;volume=37&amp;publication_year=2016&amp;pages=3588-95&amp;pmid=27572070&amp;doi=10.1093/eurheartj/ehw388&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R25">
<span class="label">25.</span><cite>Ginsberg HN, Rader DJ, Raal FJ, et al.  Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc Drugs Ther. 2016;30:473–83. doi: 10.1007/s10557-016-6685-y.</cite> [<a href="https://doi.org/10.1007/s10557-016-6685-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5055560/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27618825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Drugs%20Ther&amp;title=Efficacy%20and%20safety%20of%20alirocumab%20in%20patients%20with%20heterozygous%20familial%20hypercholesterolemia%20and%20LDL-C%20of%20160%20mg/dl%20or%20higher&amp;author=HN%20Ginsberg&amp;author=DJ%20Rader&amp;author=FJ%20Raal&amp;volume=30&amp;publication_year=2016&amp;pages=473-83&amp;pmid=27618825&amp;doi=10.1007/s10557-016-6685-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R26">
<span class="label">26.</span><cite>Blom DJ, Harada-Shiba M, Rubba P, et al.  Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial. J Am Coll Cardiol. 2020;76:131–42. doi: 10.1016/j.jacc.2020.05.027.</cite> [<a href="https://doi.org/10.1016/j.jacc.2020.05.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32646561/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Efficacy%20and%20safety%20of%20alirocumab%20in%20adults%20with%20homozygous%20familial%20hypercholesterolemia:%20the%20ODYSSEY%20HoFH%20trial&amp;author=DJ%20Blom&amp;author=M%20Harada-Shiba&amp;author=P%20Rubba&amp;volume=76&amp;publication_year=2020&amp;pages=131-42&amp;pmid=32646561&amp;doi=10.1016/j.jacc.2020.05.027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R27">
<span class="label">27.</span><cite>Raal F, Scott R, Somaratne R, et al.  Low-density lipoprotein cholesterol–lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia. Circulation. 2012;126:2408–17. doi: 10.1161/CIRCULATIONAHA.112.144055.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.112.144055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23129602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Low-density%20lipoprotein%20cholesterol%E2%80%93lowering%20effects%20of%20AMG%20145,%20a%20monoclonal%20antibody%20to%20proprotein%20convertase%20subtilisin/kexin%20type%209%20serine%20protease%20in%20patients%20with%20heterozygous%20familial%20hypercholesterolemia&amp;author=F%20Raal&amp;author=R%20Scott&amp;author=R%20Somaratne&amp;volume=126&amp;publication_year=2012&amp;pages=2408-17&amp;pmid=23129602&amp;doi=10.1161/CIRCULATIONAHA.112.144055&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R28">
<span class="label">28.</span><cite>Raal FJ, Stein EA, Dufour R, et al.  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. The Lancet. 2015;385:331–40. doi: 10.1016/S0140-6736(14)61399-4.</cite> [<a href="https://doi.org/10.1016/S0140-6736(14)61399-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25282519/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Lancet&amp;title=PCSK9%20inhibition%20with%20evolocumab%20(AMG%20145)%20in%20heterozygous%20familial%20hypercholesterolaemia%20(RUTHERFORD-2):%20a%20randomised,%20double-blind,%20placebo-controlled%20trial&amp;author=FJ%20Raal&amp;author=EA%20Stein&amp;author=R%20Dufour&amp;volume=385&amp;publication_year=2015&amp;pages=331-40&amp;pmid=25282519&amp;doi=10.1016/S0140-6736(14)61399-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R29">
<span class="label">29.</span><cite>Raal FJ, Honarpour N, Blom DJ, et al.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. The Lancet. 2015;385:341–50. doi: 10.1016/S0140-6736(14)61374-X.</cite> [<a href="https://doi.org/10.1016/S0140-6736(14)61374-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25282520/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Lancet&amp;title=Inhibition%20of%20PCSK9%20with%20evolocumab%20in%20homozygous%20familial%20hypercholesterolaemia%20(TESLA%20Part%20B):%20a%20randomised,%20double-blind,%20placebo-controlled%20trial&amp;author=FJ%20Raal&amp;author=N%20Honarpour&amp;author=DJ%20Blom&amp;volume=385&amp;publication_year=2015&amp;pages=341-50&amp;pmid=25282520&amp;doi=10.1016/S0140-6736(14)61374-X&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R30">
<span class="label">30.</span><cite>Chai M, He Y, Zhao W, et al.  Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2) BMC Med. 2023;21 doi: 10.1186/s12916-023-02797-8.</cite> [<a href="https://doi.org/10.1186/s12916-023-02797-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9976471/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36855099/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Med&amp;title=Efficacy%20and%20safety%20of%20tafolecimab%20in%20Chinese%20patients%20with%20heterozygous%20familial%20hypercholesterolemia:%20a%20randomized,%20double-blind,%20placebo-controlled%20phase%203%20trial%20(CREDIT-2)&amp;author=M%20Chai&amp;author=Y%20He&amp;author=W%20Zhao&amp;volume=21&amp;publication_year=2023&amp;pmid=36855099&amp;doi=10.1186/s12916-023-02797-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R31">
<span class="label">31.</span><cite>Raal F, Durst R, Bi R, et al.  Efficacy, Safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149:354–62. doi: 10.1161/CIRCULATIONAHA.122.063460.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.122.063460" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10815002/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37850379/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Efficacy,%20Safety,%20and%20tolerability%20of%20inclisiran%20in%20patients%20with%20homozygous%20familial%20hypercholesterolemia:%20results%20from%20the%20ORION-5%20randomized%20clinical%20trial&amp;author=F%20Raal&amp;author=R%20Durst&amp;author=R%20Bi&amp;volume=149&amp;publication_year=2024&amp;pages=354-62&amp;pmid=37850379&amp;doi=10.1161/CIRCULATIONAHA.122.063460&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R32">
<span class="label">32.</span><cite>Raal FJ, Kallend D, Ray KK, et al.  Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520–30. doi: 10.1056/NEJMoa1913805.</cite> [<a href="https://doi.org/10.1056/NEJMoa1913805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32197277/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Inclisiran%20for%20the%20treatment%20of%20heterozygous%20familial%20hypercholesterolemia&amp;author=FJ%20Raal&amp;author=D%20Kallend&amp;author=KK%20Ray&amp;volume=382&amp;publication_year=2020&amp;pages=1520-30&amp;pmid=32197277&amp;doi=10.1056/NEJMoa1913805&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R33">
<span class="label">33.</span><cite>Yamashita S, Kiyosue A, Maheux P, et al.  Efficacy, safety, and pharmacokinetics of inclisiran in japanese patients: results from ORION-15. J Atheroscler Thromb. 2024;31:876–903. doi: 10.5551/jat.64454.</cite> [<a href="https://doi.org/10.5551/jat.64454" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11150722/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38220186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Atheroscler%20Thromb&amp;title=Efficacy,%20safety,%20and%20pharmacokinetics%20of%20inclisiran%20in%20japanese%20patients:%20results%20from%20ORION-15&amp;author=S%20Yamashita&amp;author=A%20Kiyosue&amp;author=P%20Maheux&amp;volume=31&amp;publication_year=2024&amp;pages=876-903&amp;pmid=38220186&amp;doi=10.5551/jat.64454&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R34">
<span class="label">34.</span><cite>Huo Y, Lesogor A, Lee CW, et al.  Efficacy and safety of inclisiran in Asian patients: results from ORION-18. 
JACC Asia
. 2024;4:123–34. doi: 10.1016/j.jacasi.2023.09.006.</cite> [<a href="https://doi.org/10.1016/j.jacasi.2023.09.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10866732/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38371290/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Asia&amp;title=Efficacy%20and%20safety%20of%20inclisiran%20in%20Asian%20patients:%20results%20from%20ORION-18&amp;author=Y%20Huo&amp;author=A%20Lesogor&amp;author=CW%20Lee&amp;volume=4&amp;publication_year=2024&amp;pages=123-34&amp;pmid=38371290&amp;doi=10.1016/j.jacasi.2023.09.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R35">
<span class="label">35.</span><cite>Keech AC, Oyama K, Sever PS, et al.  Efficacy and safety of long-term evolocumab use among Asian subjects - a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Circ J. 2021;85:2063–70. doi: 10.1253/circj.CJ-20-1051.</cite> [<a href="https://doi.org/10.1253/circj.CJ-20-1051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33980763/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20J&amp;title=Efficacy%20and%20safety%20of%20long-term%20evolocumab%20use%20among%20Asian%20subjects%20-%20a%20subgroup%20analysis%20of%20the%20further%20cardiovascular%20outcomes%20research%20with%20PCSK9%20inhibition%20in%20subjects%20with%20elevated%20risk%20(FOURIER)%20trial&amp;author=AC%20Keech&amp;author=K%20Oyama&amp;author=PS%20Sever&amp;volume=85&amp;publication_year=2021&amp;pages=2063-70&amp;pmid=33980763&amp;doi=10.1253/circj.CJ-20-1051&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R36">
<span class="label">36.</span><cite>Scicali R, Di Pino A, Ferrara V, et al.  Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting. Acta Diabetol. 2021;58:949–57. doi: 10.1007/s00592-021-01703-z.</cite> [<a href="https://doi.org/10.1007/s00592-021-01703-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8187232/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33745063/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Diabetol&amp;title=Effect%20of%20PCSK9%20inhibitors%20on%20pulse%20wave%20velocity%20and%20monocyte-to-HDL-cholesterol%20ratio%20in%20familial%20hypercholesterolemia%20subjects:%20results%20from%20a%20single-lipid-unit%20real-life%20setting&amp;author=R%20Scicali&amp;author=A%20Di%20Pino&amp;author=V%20Ferrara&amp;volume=58&amp;publication_year=2021&amp;pages=949-57&amp;pmid=33745063&amp;doi=10.1007/s00592-021-01703-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R37">
<span class="label">37.</span><cite>Bosco G, Di Giacomo Barbagallo F, Di Marco M, et al.  Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience. Prog Cardiovasc Dis. 2025 doi: 10.1016/j.pcad.2025.05.008.</cite> [<a href="https://doi.org/10.1016/j.pcad.2025.05.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40436259/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prog%20Cardiovasc%20Dis&amp;title=Effect%20of%20inclisiran%20on%20lipid%20and%20mechanical%20vascular%20profiles%20in%20familial%20hypercholesterolemia%20subjects:%20results%20from%20a%20single%20lipid%20center%20real-world%20experience&amp;author=G%20Bosco&amp;author=F%20Di%20Giacomo%20Barbagallo&amp;author=M%20Di%20Marco&amp;publication_year=2025&amp;pmid=40436259&amp;doi=10.1016/j.pcad.2025.05.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R38">
<span class="label">38.</span><cite>Gargiulo P, Basile C, Cesaro A, et al.  Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT) Atherosclerosis. 2023;366:32–9. doi: 10.1016/j.atherosclerosis.2023.01.001.</cite> [<a href="https://doi.org/10.1016/j.atherosclerosis.2023.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36696749/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Atherosclerosis&amp;title=Efficacy,%20safety,%20adherence%20and%20persistence%20of%20PCSK9%20inhibitors%20in%20clinical%20practice:%20a%20single%20country,%20multicenter,%20observational%20study%20(AT-TARGET-IT)&amp;author=P%20Gargiulo&amp;author=C%20Basile&amp;author=A%20Cesaro&amp;volume=366&amp;publication_year=2023&amp;pages=32-9&amp;pmid=36696749&amp;doi=10.1016/j.atherosclerosis.2023.01.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R39">
<span class="label">39.</span><cite>Casula M, Gazzotti M, Bonaiti F, et al.  Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. J Intern Med. 2021;290:116–28. doi: 10.1111/joim.13219.</cite> [<a href="https://doi.org/10.1111/joim.13219" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8359216/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33259671/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Intern%20Med&amp;title=Reported%20muscle%20symptoms%20during%20statin%20treatment%20amongst%20Italian%20dyslipidaemic%20patients%20in%20the%20real-life%20setting:%20the%20PROSISA%20Study&amp;author=M%20Casula&amp;author=M%20Gazzotti&amp;author=F%20Bonaiti&amp;volume=290&amp;publication_year=2021&amp;pages=116-28&amp;pmid=33259671&amp;doi=10.1111/joim.13219&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R40">
<span class="label">40.</span><cite>Ma W, Guo X, Ma Y, et al.  Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe/placebo in patients at high cardiovascular risk. Atherosclerosis. 2021;326:25–34. doi: 10.1016/j.atherosclerosis.2021.04.008.</cite> [<a href="https://doi.org/10.1016/j.atherosclerosis.2021.04.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34004550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Atherosclerosis&amp;title=Meta-analysis%20of%20randomized%20clinical%20trials%20comparing%20PCSK9%20monoclonal%20antibody%20versus%20ezetimibe/placebo%20in%20patients%20at%20high%20cardiovascular%20risk&amp;author=W%20Ma&amp;author=X%20Guo&amp;author=Y%20Ma&amp;volume=326&amp;publication_year=2021&amp;pages=25-34&amp;pmid=34004550&amp;doi=10.1016/j.atherosclerosis.2021.04.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R41">
<span class="label">41.</span><cite>Brandts J, Dharmayat KI, Vallejo-Vaz AJ, et al.  A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021;325:46–56. doi: 10.1016/j.atherosclerosis.2021.03.042.</cite> [<a href="https://doi.org/10.1016/j.atherosclerosis.2021.03.042" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33901739/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Atherosclerosis&amp;title=A%20meta-analysis%20of%20medications%20directed%20against%20PCSK9%20in%20familial%20hypercholesterolemia&amp;author=J%20Brandts&amp;author=KI%20Dharmayat&amp;author=AJ%20Vallejo-Vaz&amp;volume=325&amp;publication_year=2021&amp;pages=46-56&amp;pmid=33901739&amp;doi=10.1016/j.atherosclerosis.2021.03.042&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R42">
<span class="label">42.</span><cite>Kersten S. ANGPTL3 as therapeutic target. Curr Opin Lipidol. 2021;32:335–41. doi: 10.1097/MOL.0000000000000789.</cite> [<a href="https://doi.org/10.1097/MOL.0000000000000789" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8631155/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34581310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Opin%20Lipidol&amp;title=ANGPTL3%20as%20therapeutic%20target&amp;author=S%20Kersten&amp;volume=32&amp;publication_year=2021&amp;pages=335-41&amp;pmid=34581310&amp;doi=10.1097/MOL.0000000000000789&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>online supplemental file 1</span></div>
<div class="media p">
<div class="caption">
<a href="/articles/instance/12374655/bin/openhrt-12-2-s001.tif" data-ga-action="click_feat_suppl" class="usa-link">openhrt-12-2-s001.tif</a><sup> (748.8KB, tif) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/openhrt-2025-003490</div>
</div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p"><span>online supplemental file 3</span></div>
<div class="media p">
<div class="caption">
<a href="/articles/instance/12374655/bin/openhrt-12-2-s002.docx" data-ga-action="click_feat_suppl" class="usa-link">openhrt-12-2-s002.docx</a><sup> (4.6MB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/openhrt-2025-003490</div>
</div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="caption p"><span>online supplemental file 4</span></div>
<div class="media p">
<div class="caption">
<a href="/articles/instance/12374655/bin/openhrt-12-2-s003.docx" data-ga-action="click_feat_suppl" class="usa-link">openhrt-12-2-s003.docx</a><sup> (41.3KB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/openhrt-2025-003490</div>
</div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Data are available in a public, open access repository.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Open Heart are provided here courtesy of <strong>BMJ Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1136/openhrt-2025-003490"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/openhrt-12-2.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (5.3 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374655/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374655/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374655%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374655/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374655/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374655/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40841123/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374655/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40841123/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374655/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374655/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="mLbzeeBZYoHmuxvr3XCf8qcNnONkG3NOo2Fy9czPzmvWzyV8pP3dOC1a9efA8pnx">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
